Researchers gave rats with spinal cord injuries a daily intravenous dose of a four-amino-acid peptide called CAQK, and the molecule did something most drugs cannot. It found the injury on its own. Eight weeks later the treated animals were using the injured forelimb close to normal, while untreated animals stayed severely impaired.
The work, published online June 30 in the Journal of Trauma and Acute Care Surgery ↗, comes from surgeons at UC Davis and the Uniformed Services University of the Health Sciences. It is small and preclinical, twelve rats in total, and every number below carries that caveat.
Target the drug, not the target
CAQK is a homing peptide. The usual way to design a drug is to shape a molecule that fits a receptor, then hope enough of it reaches the right tissue. A homing peptide flips the emphasis to delivery: it is a short sequence that accumulates wherever a particular kind of damage is, so the address does the work. CAQK homes to sites of central nervous system injury. Earlier work from the same group showed it collects in traumatic brain injury and, after an intravenous injection, in injured spinal cord. This study asked the obvious follow-up. Does getting the peptide there actually help the animal recover?
What the rats did
Twelve female rats received a hemicontusion, a one-sided bruising injury, to the right side of the spinal cord at the cervical C5 level, high in the neck. Starting one hour after injury, half got intravenous CAQK (2.5 mg per kg) once a day for a week, and half got saline. Forelimb recovery was scored on the Irvine, Beatties and Bresnahan scale, which runs from 0 (no use) to 9 (normal movement).
By week eight, CAQK-treated rats scored a median of 7 and saline rats scored 3 (p = 0.01, meaning a gap this size is unlikely to be chance). The treated animals were significantly ahead at weeks 1, 2, 5 and 8, not just at the end.
Two tissue measurements point at why. Astrocytes, the cells that build the dense scar that walls off nerve regrowth after spinal injury, were far less activated in treated cords (a GFAP marker of 0.1 versus 0.7, p = 0.002). The nerve fibers themselves were better preserved (an NFM axonal marker of 0.3 versus 0.1, p = 0.03). In a dish, CAQK also kept neurons wired into more complex networks than untreated cells. Less scarring, more surviving wiring, and a better score, in the same experiment.
Why delivery is the hard part
Spinal cord injury has almost no approved drug therapy, and part of the reason is plumbing. Getting a drug into the injured cord, at the right place and in the first hours, usually means injecting into or around the cord itself. A molecule dripped into a vein that then concentrates itself at the lesion sidesteps that problem. It is also where peptides have a structural edge. A short sequence that recognizes a diseased microenvironment is easier to find and cheaper to make than an antibody, and it can either carry a payload or, as here, appear to do something useful on its own.
The honest limits are large. Twelve rats, one injury model, one lab, and a median score of 7 that is better but still not normal. There is no human data, and the paper reports the median rather than every animal. Whether intravenous CAQK does anything in a human spinal cord, on the messy timeline of a real trauma, is unknown. What the study establishes is narrower and still worth the attention. Steer a peptide to the injured cord early, and in this model the cord scars less and the animal moves more.
peptidemodel does not host a card for CAQK, which is a research homing peptide rather than a clinical drug. But the strategy it represents sits across two of the site's target themes, neuroprotective ↗ peptides and tissue-repair ↗ peptides. Most entries under those themes are molecules built to act on a receptor. CAQK is a reminder that a peptide's sequence can be the address label instead of the message.